SRRK Insider Trading

Insider Ownership Percentage: 19.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $67,569,198.50

Scholar Rock Insider Trading History Chart

This chart shows the insider buying and selling history at Scholar Rock by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$11MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Scholar Rock Share Price & Price History

Current Price: $34.60
Price Change: Price Increase of +0.05 (0.14%)
As of 03/14/2025 05:00 PM ET

This chart shows the closing price history over time for SRRK up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$34.60Closing price on 03/14/25:

SEC Filings (Institutional Ownership Changes) for Scholar Rock (NASDAQ:SRRK)

91.08% of Scholar Rock stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SRRK by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$937Mbought$297MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$500M$0$500MTotal InflowsTotal Outflows
Scholar Rock logo
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More on Scholar Rock

Today's Range

Now: $34.60
Low: $34.53
High: $36.34

50 Day Range

MA: $39.68
Low: $34.50
High: $46.73

52 Week Range

Now: $34.60
Low: $6.76
High: $46.98

Volume

1,093,825 shs

Average Volume

1,164,015 shs

Market Capitalization

$3.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Who are the company insiders with the largest holdings of Scholar Rock?

Scholar Rock's top insider shareholders include:
  1. Public Equities LP Invus (Major Shareholder)
  2. Samsara Biocapital Gp, Llc (Major Shareholder)
  3. Srinivas Akkaraju (Director)
  4. Jay T Backstrom (CEO)
  5. Edward H Myles (CFO)
  6. Junlin Ho (General Counsel)
  7. Caryn Parlavecchio (Insider)
  8. Mo Qatanani (Insider)
  9. Mo Qatanani (SVP)
  10. Jing L Marantz (Insider)
  11. Tracey Sacco (Insider)
Learn More about top insider investors at Scholar Rock.

Who are the major institutional investors of Scholar Rock?

Scholar Rock's top institutional shareholders include:
  1. FMR LLC — 14.57%
  2. Price T Rowe Associates Inc. MD — 9.92%
  3. Samsara BioCapital LLC — 6.00%
  4. Vanguard Group Inc. — 5.07%
  5. Redmile Group LLC — 4.86%
  6. Marshall Wace LLP — 3.15%
Learn More about top institutional investors of Scholar Rock stock.

Which institutional investors are selling Scholar Rock stock?

In the last quarter, SRRK stock was sold by these institutional investors:
  1. Samsara BioCapital LLC
  2. Redmile Group LLC
  3. abrdn plc
  4. Orbimed Advisors LLC
  5. Candriam S.C.A.
  6. Millennium Management LLC
  7. Clearbridge Investments LLC
  8. BIT Capital GmbH
Within the last year, company insiders that have sold Scholar Rock company stock include:
  1. Public Equities LP Invus (Major Shareholder)
  2. Samsara Biocapital Gp, Llc (Major Shareholder)
  3. Srinivas Akkaraju (Director)
  4. Jay T Backstrom (CEO)
  5. Edward H Myles (CFO)
  6. Junlin Ho (General Counsel)
  7. Caryn Parlavecchio (Insider)
  8. Mo Qatanani (Insider)
  9. Mo Qatanani (SVP)
Learn More investors selling Scholar Rock stock.

Which institutional investors are buying Scholar Rock stock?

Within the previous quarter, SRRK stock was acquired by institutional investors including:
  1. FMR LLC
  2. Marshall Wace LLP
  3. Norges Bank
  4. Fairmount Funds Management LLC
  5. Adage Capital Partners GP L.L.C.
  6. Wellington Management Group LLP
  7. Janus Henderson Group PLC
  8. Loomis Sayles & Co. L P
Within the previous year, these company insiders have bought Scholar Rock stock:
  1. Public Equities LP Invus (Major Shareholder)
  2. Samsara Biocapital Gp, Llc (Major Shareholder)
Learn More investors buying Scholar Rock stock.